<DOC>
	<DOCNO>NCT02393131</DOCNO>
	<brief_summary>Brain metastasis common brain tumor adult . It estimate around 10-30 % cancer patient would develop brain metastasis course illness . Whole brain radiotherapy ( WBRT ) treatment choice majority patient brain metastasis . WBRT yield high radiologic response rate ( 27~56 % ) effective rapid palliation neurologic symptom well prolongs time neurocognitive function decline cause intracranial lesion . By use conventional fractionation , 33 % patient develop late neurocognitive toxicity memory impairment common symptom . The incidence even high formal sensitive neurocognitive assessment prospectively evaluate . With long-term survivor nowadays , become increasingly important minimize neurocognitive function decline maintain quality life patient brain metastasis . The function hippocampus cooperation learning , consolidation retrieval information essential formation new memory . Bilateral unilateral radiation injury hippocampus know alter learn memory formation . Several preclinical study support hypothesis hippocampus-mediated cognitive dysfunction ionize radiation . Clinical study show increase radiation dose hippocampus associate subsequent neurocognitive function impairment adult pediatric patient . Furthermore , preliminary result Radiation Therapy Oncology Group ( RTOG ) 0933 suggest hippocampal avoidance significant reduce mean relative decline 4 month 30 % historical cohort WBRT 7 % experimental cohort . Previous study show brain structure hippocampus also associate radiation-induced decline neurocognitive function . There presence placebo effect intervention seek improvement neurocognitive function . In present study , single blind randomize phase II trial design investigate effectiveness neurocognitive function preservation use conformal WBRT without hippocampal avoidance .</brief_summary>
	<brief_title>Neurocognitive Outcome Conformal WBRT w/wo Hippocampal Avoidance Brain Metastases</brief_title>
	<detailed_description>This single institutional , randomized phase II study assess neurocognitive outcome conformal WBRT without hippocampal avoidance patient multiple brain metastasis . Patients randomly assign 1:1 receive conformal WBRT without hippocampal avoidance use permuted block within stratum define Graded Prognostic Assessment ( GPA ) score baseline neurocognitive status . All patient co-investigators except principal investigator attend radiation oncologist blind treatment group . The whole brain planning target volume ( PTV ) receive 30 Gy 10 fraction . Treatment deliver daily , 5 fraction per week , 2 2.5 week . Breaks treatment minimize . Hippocampal Avoidance WBRT : The dose prescribe 90 % cranial content PTV cover prescription dose . Maximum dose 2 % PTV ( D2 % ) 37.5 Gy , minimum dose 98 % PTV ( D98 % ) 25 Gy . Minimum dose 100 % hippocampal avoidance region 10 Gy , dose point within hippocampal avoidance region exceed 17 Gy . Conformal WBRT : The dose prescribe 95 % cranial content PTV cover prescription dose . Maximum dose 1 % PTV ( D1 % ) 36 Gy , minimum dose 99 % PTV ( D99 % ) 27 Gy . Follow-up &amp; Assessment Side effect evaluation : - Acute ( ≤ 90 day WBRT start ) toxicity ( CTCAE ver.4 ) - Late ( &gt; 90 day WBRT start ) toxicity ( CTCAE ver.4 ) Functional evaluation : baseline , 2- , 4- , 6-month , every 3 month 12 month intracranial disease progression death WBRT - Neurocognitive function - Self-reported cognitive functioning ( two item EORTC Quality Life Questionnaire-C30 Taiwan ) - Health-related quality life specific brain neoplasm ( EORTC Quality Life Questionnaire-Brain Neoplasm Taiwan ) Efficacy evaluation : - Follow-up brain MRI 4- , 9- , 12-month intracranial disease progression , death . - Overall survival</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Inclusion criterion : To eligible inclusion , patient must fulfill follow criterion : 1 . Patients histologic diagnosis nonhematopoietic malignancy radiographic evidence brain metastasis 2 . Patients brain metastasis outside 5mm margin around either hippocampus gadolinium contrast enhance MRI obtain within 30 day prior registration 3 . Patients brain metastasis treat stereotactic radiosurgery ( SRS ) ￼￼received SRS for￼≤ 5 intracranial ￼metastatic ￼lesions 4 . No evidence leptomeningeal metastasis gadoliniumenhanced MRI within 30 day prior registration 5 . Age ≥ 20 year 6 . Karnofsky Performance Status ≥ 60 % 7 . Life expectancy ≥ 4 month . 8 . Women childbearing potential male participant must practice adequate contraception 9 . Patients must able comply study protocol followup schedule provide study specific inform consent Exclusion criterion : Patients fulfill follow criterion exclude trial 1 . Prior radiotherapy brain SRS &gt; 5 intracranial metastatic lesion ( ) biological equivalent dose 2Gy fraction great 7.3 Gy 40 % volume bilateral hippocampus prior SRS 2 . Serum creatinine &gt; 2.0 mg/dL within 30 day prior registration 3 . Contraindication MRI implant metal device foreign body , severe claustrophobia 4 . Patients leptomeningeal metastasis 5 . Severe , active comorbidities , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety adverse event protocol , limit compliance study requirement , define follow : 1 . Uncontrolled active infection require intravenous antibiotic time registration 2 . Transmural myocardial infarction ≤ 6 month prior registration 3 . Unstable angina congestive heart failure require hospitalization ≤ 6 month prior registration 4 . Lifethreatening uncontrolled clinically significant cardiac arrhythmia 5 . Hepatic insufficiency result clinical jaundice and/or coagulation defect 6 . Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy time registration 7 . Uncontrolled psychiatric disorder 8 . Uncontrolled , clinically significant cardiac arrhythmia 6 . Will receive investigational agent chemotherapy and/or target therapy WBRT 7 . Women childbearing potential male participant sexually active willing/able use medically acceptable form contraception ; exclusion necessary radiation treatment involve study may significantly teratogenic</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Brain Metastases</keyword>
	<keyword>Whole Brain Radiotherapy</keyword>
	<keyword>Neurocognitive function</keyword>
</DOC>